Amyloidosis: Diagnosis, Treatment, Outcomes
Amyloidosis: Diagnosis, Treatment, Outcomes is a research topic within Molecular Biology. Science Explorer counts 22k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the molecular mechanisms, diagnosis, treatment, and prognosis of amyloidosis, with a particular emphasis on transthyretin-related cardiac and familial amyloid polyneuropathy. It covers topics such as RNAi therapy, cardiovascular magnetic resonance, and immunoglobulin light chain involvement.
- Transthyretin
- Cardiac Amyloidosis
- Light Chain Amyloidosis
- RNAi Therapy
- Diagnosis
- Treatment
- Prognosis
- Familial Amyloid Polyneuropathy
- Immunoglobulin Light Chain
- Cardiovascular Magnetic Resonance
- Research works
- 22k fractional, since 1950
- In the world top 10%
- 2.2k per year above
- Top-10% rate
- 10.1% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- +28% the tick is no change
- Largest producer
United States
42% of the 10 largest, 2022-now
Which countries lead Amyloidosis: Diagnosis, Treatment, Outcomes research?
By volume, the United States and China publish the most (1.6k and 456 works in 2022-now).
By volume, 2022-now
- 1
United States 1.6k works
- 2
China 456 works
- 3
Japan 396 works
- 4
Italy 329 works
- 5
India 227 works
- 6
France 206 works
- 7
Spain 186 works
- 8
United Kingdom 182 works
- 9
Germany 163 works
- 10
Brazil 114 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Amyloidosis: Diagnosis, Treatment, Outcomes research?
By volume in 2022-now, Mayo Clinic publishes the most Amyloidosis: Diagnosis, Treatment, Outcomes research, followed by Harvard University and University College London.
By volume, 2022-now
- 1
Mayo Clinic
United States 109 works
- 2
Harvard University
United States 60 works
- 3
University College London
United Kingdom 55 works
- 4
Cleveland Clinic
United States 53 works
- 5
Columbia University
United States 45 works
- 6
Kumamoto University
Japan 31 works
- 7
Peking University
China 27 works
- 8
Chinese Academy of Medical Sciences & Peking Union Medical College
China 27 works
- 9
Inserm
France 25 works
- 10
Amyloidosis Foundation
United States 25 works
Who are the leading researchers in Amyloidosis: Diagnosis, Treatment, Outcomes?
The most-cited researchers publishing on Amyloidosis: Diagnosis, Treatment, Outcomes include John J.V. McMurray, Stephan Windecker and Giuseppe Remuzzi.
- 1
John J.V. McMurray
United Kingdom 349k citations
- 2
Stephan Windecker
Switzerland 338k citations
- 3
Giuseppe Remuzzi
Italy 328k citations
- 4
Graeme J. Hankey
Australia 316k citations
- 5
Gregory Y.H. Lip
United Kingdom 311k citations
- 6
John Q. Trojanowski
United States 286k citations
- 7
Hagop M. Kantarjian
United States 273k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Amyloidosis: Diagnosis, Treatment, Outcomes research done?
The largest centres of Amyloidosis: Diagnosis, Treatment, Outcomes research in 2022-now are New York (United States), Beijing (China), London (United Kingdom) and Boston (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Clarkston, Kumamoto and Rochester.
Largest cities, 2022-now
- 1
New York
United States 107 works
- 2
Beijing
China 105 works
- 3
London
United Kingdom 97 works
- 4
Boston
United States 94 works
- 5
Tokyo
Japan 86 works
- 6
Paris
France 72 works
- 7
Cleveland
United States 60 works
- 8
Rome
Italy 50 works
- 9
Madrid
Spain 50 works
- 10
Philadelphia
United States 47 works
Where it is the local speciality
- ClarkstonUS · 24.6 works1058×
- KumamotoJP · 33.6 works31×
- RochesterUS · 41.1 works20×
- ScottsdaleUS · 37.0 works15×
Location quotient: how much more of its research is in Amyloidosis: Diagnosis, Treatment, Outcomes than the world average.
Where is the best place to study Amyloidosis: Diagnosis, Treatment, Outcomes?
Among universities, judged by research, University College London, Columbia University and Harvard University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.
Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.
Every institution in Amyloidosis: Diagnosis, Treatment, Outcomes, country by countryIs Amyloidosis: Diagnosis, Treatment, Outcomes research growing?
Output in 2022-2025 was 28% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Amyloidosis: Diagnosis, Treatment, Outcomes.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Amyloidosis: Diagnosis, Treatment, Outcomes as a percentage of every work published that year, 0.021% in 2024.
Fractional works of Amyloidosis: Diagnosis, Treatment, Outcomes over all fractional works that year. How the balance of science has shifted.
How much of it reaches the world top 10%
Year by year.
Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.
Discussion
Ask a question or share a note about Amyloidosis: Diagnosis, Treatment, Outcomes. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.